Response Pharmaceuticals, Inc., has unveiled significant findings from its Phase 1b clinical trial of RDX-002, signaling a potential breakthrough in combatting antipsychotic-induced weight gain (AIWG).
Clerkenwell Health is proud to announce the launch of its foundation course for Psychedelic-Assisted Therapy, a comprehensive 30-hour program that brings together leading experts in the field.
Response Pharmaceuticals, Inc., has unveiled significant findings from its Phase 1b clinical trial of RDX-002, signaling a potential breakthrough in combatting antipsychotic-induced weight gain (AIWG).
Pacylex Pharmaceuticals Inc. has announced the presentation of phase 1 safety and efficacy findings for small molecule drug zelenirstat for cancer treatment.
Kynos Therapeutics Ltd, based in Edinburgh, UK, focuses on developing small molecule kynurenine 3-monooxygenase (KMO) inhibitors for inflammatory disorders.